NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Equality impact assessment

IPG628 Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

Briefing

1. Have any potential equality issues been identified during the briefing process (development of the brief or discussion at the committee meeting), and, if so, what are they?

Age: Non-muscle-invasive bladder cancer is more common in people aged over 60.

Socioeconomic: Bladder cancer prevalence and mortality in England are more common in people living in the most deprived areas.

Race: Bladder cancer is more common in White people than in Asian or Black people.

Disability: All people with cancer and therefore patients with bladder cancer are covered by the disability provision of the Equality Act 2010 from the point of diagnosis.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? (If there are exclusions listed in the brief (for example, populations, treatments or settings), are these justified?)

This was not thought to have an impact on the assessment of the procedure. No exclusions were applied.


3.	Has any change to the brief (such as additional issues raised during the committee meeting) been agreed to highlight potential equality issues?	
No		
4.	Have any additional stakeholders related to potential equality issues been identified during the committee meeting, and, if so, have changes to the stakeholder list been made?'	
No		
Consultation		
1.		
No specific data relating to the potential issues mentioned earlier was identified in the literature presented in the overview.		
	process been addressed by the committee, and, if so, how? pecific data relating to the potential issues mentioned earlier was	
	process been addressed by the committee, and, if so, how? pecific data relating to the potential issues mentioned earlier was	

3.	Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No	
4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No	
5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
Not applicable	
6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligation to promote equality?
Not applicable	
7.	Have the committee's considerations of equality issues been described in the consultation document, and, if so, where?
No	

Approved by Programme Director and Clinical Advisor

Date: 31/07/2018

Final interventional procedures document



2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

Have the committee's considerations of equality issues been described in the final interventional procedures document, and, if so, where?

Approved by Acting Programme Director

Date: 9 August 2018